Elevated clozapine levels and toxic effects after SARS-CoV-2 vaccination
Open Access
- 5 March 2021
- journal article
- editorial
- Published by CMA Impact Inc. in Journal of Psychiatry and Neuroscience
- Vol. 46 (2), E210-E211
- https://doi.org/10.1503/jpn.210027
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Consensus statement on the use of clozapine during the COVID-19 pandemicJournal of Psychiatry and Neuroscience, 2020
- Clozapine is strongly associated with the risk of pneumonia and inflammationGeneral Psychiatry, 2020
- A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical PharmacopsychologyPsychotherapy and Psychosomatics, 2020
- RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trialVaccine, 2019
- Role of C-Reactive Protein at Sites of Inflammation and InfectionFrontiers in Immunology, 2018
- Elevated clozapine levels associated with infection: A systematic reviewSchizophrenia Research, 2018
- Immunomodulatory effects of clozapine and their clinical implications: What have we learned so far?Schizophrenia Research, 2012
- Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune responseVaccine, 2012
- Effect of influenza vaccine on markers of inflammation and lipid profileJournal of Laboratory and Clinical Medicine, 2005
- Effect of influenza vaccination on serum clozapine and its main metabolite concentrations in patients with schizophrenia.European Journal of Clinical Pharmacology, 2001